Literature DB >> 12811779

Comparison between impairment and disability scales in immune-mediated polyneuropathies.

Ingemar S J Merkies1, Paul I M Schmitz, Frans G A Van Der Meché, Pieter A Van Doorn.   

Abstract

The ability of a scale to detect clinical relevant changes over time, i.e., its "responsiveness," may help clinicians to choose among valid and reliable measures. Therefore, we investigated the responsiveness' rank ordering (best to worse) of six selected valid and reliable scales, namely the Medical Research Council (MRC)-sumscore, sensory-sumscore, grip-strength (Vigorimeter), nine-hole peg, ten-meters walking, and a disability-sumscore, in immune-mediated polyneuropathies. Patients with newly diagnosed Guillain-Barré syndrome (n = 7) or chronic inflammatory demyelinating polyneuropathy (n = 13) were examined over 52 weeks. Responsiveness of each scale was measured using different methods (effect-size, standardized response mean score, Wilcoxon matched-pairs signed-rank, and a newly devised Schmitz's distribution-free responsiveness score), and the obtained scores in each method were plotted against the follow-up period, thus allowing area-under-the-curve calculations (higher area-under-the-curve indicating better responsiveness). Also, longitudinal correlations were performed between the scales' values and patients' own clinical judgments (deteriorated, unchanged, improved) (higher correlation = better responsiveness). A consistent rank ordering was observed in each technique with the disability-sumscore, MRC-sumscore, and Vigorimeter being among the best responsive scales. Hence, the primary use of these measures is suggested in studies of immune-mediated polyneuropathies. Copyright 2003 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12811779     DOI: 10.1002/mus.10410

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  10 in total

1.  A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale.

Authors:  R C Graham; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-30       Impact factor: 10.154

2.  Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.

Authors:  M P J Garssen; P I M Schmitz; I S J Merkies; B C Jacobs; F G A van der Meché; P A van Doorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-01       Impact factor: 10.154

3.  Functional neuroimaging at different disease stages reveals distinct phases of neuroplastic changes in amyotrophic lateral sclerosis.

Authors:  Bahram Mohammadi; Katja Kollewe; Amir Samii; Reinhard Dengler; Thomas F Münte
Journal:  Hum Brain Mapp       Date:  2011-05       Impact factor: 5.038

4.  Inspiratory muscle training in a child with nemaline myopathy and organ transplantation.

Authors:  Barbara K Smith; Mark S Bleiweis; Joni Zauhar; A Daniel Martin
Journal:  Pediatr Crit Care Med       Date:  2011-03       Impact factor: 3.624

5.  Nerve conduction studies in relation to residual fatigue in Guillain-Barré syndrome.

Authors:  Marcel P J Garssen; P A van Doorn; G H Visser
Journal:  J Neurol       Date:  2006-07-17       Impact factor: 4.849

6.  Amyotrophic lateral sclerosis affects cortical and subcortical activity underlying motor inhibition and action monitoring.

Authors:  Bahram Mohammadi; Katja Kollewe; David M Cole; Anja Fellbrich; Marcus Heldmann; Amir Samii; Reinhard Dengler; Susanne Petri; Thomas F Münte; Ulrike M Krämer
Journal:  Hum Brain Mapp       Date:  2015-04-24       Impact factor: 5.038

7.  Getting closer to patients: the INCAT Overall Disability Sum Score relates better to patients' own clinical judgement in immune-mediated polyneuropathies.

Authors:  I S J Merkies; P I M Schmitz
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-03-20       Impact factor: 10.154

Review 8.  Treatment for IgG and IgA paraproteinaemic neuropathy.

Authors:  Abraham C J Stork; Michael P T Lunn; Eduardo Nobile-Orazio; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2015-03-24

9.  Neuroimaging markers of clinical progression in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kalliopi Pitarokoili; Dietrich Sturm; Adnan Labedi; Tineke Greiner; Lynn Eitner; Nina Kumowski; Elena K Enax-Krumova; Anna Lena Fisse; Christoph Maier; Ralf Gold; Martin Tegenthoff; Tobias Schmidt-Wilcke; Min-Suk Yoon
Journal:  Ther Adv Neurol Disord       Date:  2019-06-18       Impact factor: 6.570

Review 10.  Treatment of chronic inflammatory demyelinating polyneuropathy: from molecular bases to practical considerations.

Authors:  Paolo Ripellino; Thomas Fleetwood; Roberto Cantello; Cristoforo Comi
Journal:  Autoimmune Dis       Date:  2014-01-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.